Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
์ข
๋ชฉ ์ฝ๋ RENB
ํ์ฌ ์ด๋ฆLunai Bioworks Inc
์์ฅ์ผNov 18, 2014
CEOWeinstein (David)
์ง์ ์- -
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃNov 18
์ฃผ์2080 Century Park East, Suite 906
๋์LOS ANGELES
์ฆ๊ถ ๊ฑฐ๋์NASDAQ Capital Market Consolidated
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ90067
์ ํ14539179840
์น์ฌ์ดํธ
์ข
๋ชฉ ์ฝ๋ RENB
์์ฅ์ผNov 18, 2014
CEOWeinstein (David)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์